Page values for "Cariprazine"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`
brand	`String`	Vraylar
structure	`File`
classes	List of `String`, delimiter: `,`	Atypical antipsychotic • D2/D3/5HT1A partial agonist
mechanism	`String`
uses	`String`	Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022).
starting_dose	`String`	Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg.
preparations	`String`	1.5 mg, 3 mg, 4.5 mg, 6 mg capsules
fda_max	`String`	6 mg/d (psychosis/mania); 3 mg/d (depression adjunct)
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Weeks for psychosis/mood efficacy
duration	`String`	Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks)
halflife	`String`	Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses
bioavailability	`String`	Adequate oral bioavailability
pregnancy	`String`	Limited data
legal	`String`	Rx